Experimental CAR-T therapy targets rare muscle disease
NCT ID NCT07086404
First seen Jan 23, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This early-phase study tests an experimental cell therapy called GC012F in 12 people with refractory idiopathic inflammatory myopathy, a rare autoimmune disease causing muscle weakness and inflammation. Participants receive a single infusion of their own modified immune cells after a short chemotherapy-like prep. The main goal is to check safety and side effects, while also measuring how long the cells last in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY (IIM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact
Conditions
Explore the condition pages connected to this study.